Efficiency and Complication of 577-nm Laser Membranotomy for the Treatment of Retinal Sub-Inner Limiting Membrane Hemorrhage.

Front Ophthalmol (Lausanne)

Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing, China.

Published: July 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: We investigated the clinical efficiency and complications of treatment of retinal sub-inner limiting membrane (sub-ILM) hemorrhage by 577-nm semiconductive laser membranotomy.

Methods: The clinical features, ocular fundus photography, and SD-OCT image of patients who received 577-nm laser membranotomy for sub-ILM hemorrhage were assessed from January 2017 to April 2022 in this retrospective case-series study.

Results: A total of 19 patients (19 eyes) were treated for sub-ILM hemorrhage of the macula, in which eight were women and 11 were men. The age was 15-83 years (with an average age of 49.05 ± 19.41 years old). The right eye was affected in 12 patients, the left eye in seven patients. The follow-up period after laser treatment was from 0.5 to 9 months (with an average follow-up time of 3.25 ± 2.45 months). Treatment was not successful in one patient, and 577-nm laser membranotomy was successful in 18 patients (equaling a success rate of 94.74%). The best corrected visual acuity (BCVA) before laser treatment was from figure count to 40/200, and the BCVA after laser treatment was from 20/2000 to 20/20. Complications after laser treatment comprised macular hole (one patient), macular epi-membrane (one patient), vitreous hemorrhage without absorption (two patients), and sub-ILM cavity (12 patients).

Conclusions: The 577-nm laser is effective in treating sub-ILM hemorrhage and has a high success rate. Posttreatment complications should be monitored, and vitrectomy was needed with long-lasting vitreous hemorrhage and macular hole.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182147PMC
http://dx.doi.org/10.3389/fopht.2022.935188DOI Listing

Publication Analysis

Top Keywords

577-nm laser
16
sub-ilm hemorrhage
16
laser treatment
16
laser membranotomy
12
laser
9
treatment retinal
8
retinal sub-inner
8
sub-inner limiting
8
limiting membrane
8
eye patients
8

Similar Publications

Subthreshold micropulse laser treatment has proven to be an effective treatment for central serous chorioretinopathy. We report a rare case of localized macular damage following 577-nm subthreshold micropulse laser therapy in a patient with central serous chorioretinopathy in his early 40s, with 3-year longitudinal follow-up data. Pretreatment optical coherence tomography demonstrated the presence of subretinal hyperreflective material in the macular area.

View Article and Find Full Text PDF

We demonstrate nanoscale control over aggregation-induced emission (AIE) and second harmonic generation (SHG) by using optical trapping to manipulate a cyano-substituted distyrylbenzene (CDSB)-substituted polymer. The precise manipulation afforded by a tightly focused laser beam induces the formation of micrometer-sized polymer aggregates, demonstrating control over structure at the microscale. These aggregates exhibit yellow fluorescence with a prominent emissive species at 577 nm.

View Article and Find Full Text PDF

Interventions for central serous chorioretinopathy: a network meta-analysis.

Cochrane Database Syst Rev

June 2025

Eye Center, Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany.

Background: Central serous chorioretinopathy (CSC) is characterized by a thickened and dysfunctional choroid which is accompanied by a serous detachment of the neural retina. The effects on the retina are usually self-limiting, although some people are left with irreversible vision loss due to progressive and permanent photoreceptor damage or atrophy of the retinal pigment epithelium (RPE). There has been a variety of interventions used in CSC, including, but not limited to, laser treatment, photodynamic therapy (PDT), and drug therapy with mineralocorticoid receptor antagonists or intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents.

View Article and Find Full Text PDF

To report the results of Endpoint Management (EpM) with PASCAL laser in the treatment of chronic central serous retinopathy (CSR). A 577 nm yellow laser was applied using PASCAL with EpM to 11 eyes on 11 patients who were followed for CSR for at least 12 months in this prospective study. The laser spot size was set to 200 μm, the pulse duration was 15 msec, and the spot spacing was set to 0.

View Article and Find Full Text PDF

Objective: This study aims to comprehensively review and compare the safety and efficacy of commonly used lasers in the management of head and neck capillary malformations (CMs).

Data Sources: PubMed, Embase, Cochrane, and Web of Science.

Review Methods: Databases were searched from inception to August 2023.

View Article and Find Full Text PDF